Why are benzodiazepines not yet controlled substances?

JAMA Psychiatry

Volumn 72, Issue 2, 2015, Pages 110-111

  Moore, Nicholas ^a   Pariente, Antoine ^a   Bégaud, Bernard ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CONTROLLED SUBSTANCE; PRESCRIPTION DRUG;

ALZHEIMER DISEASE; AMNESIA; ANXIETY DISORDER; BENZODIAZEPINE DEPENDENCE; COGNITIVE DEFECT; DEMENTIA; DRUG FATALITY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; FALLING; GENERAL CONDITION IMPROVEMENT; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; INSOMNIA; LONG TERM EXPOSURE; MEDICAL INFORMATION; MENTAL PATIENT; PATIENT REFERRAL; PATIENT SELECTION; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; RISK BENEFIT ANALYSIS; SKIN DISEASE; SUICIDE ATTEMPT; TOXIC HEPATITIS; FEMALE; MALE; STATISTICS AND NUMERICAL DATA;

BENZODIAZEPINES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE;

EID: 84922241143     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.2190     Document Type: Editorial

References (13)

1. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States [published online December 17, 2014]. JAMA Psychiatry. doi:10 1001/jamapsychiatry. 2014. 1763.
2. Lagnaoui R, Depont F, Fourrier A, et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol. 2004; 60(7):523-529. Related article page 136
3. Fourrier A, Letenneur L, Dartigues JF, Moore N, Bégaud B. Benzodiazepine use in an elderly community-dwelling population: characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol. 2001;57(5):419-425.
4. Whitlock FA. Suicide in Brisbane 1956 to 1973: the drug-death epidemic. Med J Aust. 1975;1(24): 737-743.
5. Marks J. The Benzodiazepines: Use, Overuse, Misuse, Abuse. London, England: Springer; 1978.
6. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidentswith benzodiazepine use. Lancet. 1998;352(9137):1331-1336.
7. Orriols L, Philip P, Moore N, et al; CESIR Research Group. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther. 2011;89(4):595-601.
8. Pierfitte C, Macouillard G, Thicoïpe M, et al. Benzodiazepines and hip fractures in elderly people: case-control study. BMJ. 2001;322(7288): 704-708.
9. Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Réglat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging. 2008;25(1):61-70.
10. Lagnaoui R, Tournier M, Moride Y, et al. The risk of cognitive impairment in older communitydwelling women after benzodiazepine use. Age Ageing. 2009;38(2):226-228.
11. Billioti de Gage S, Bégaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012; 345:e6231.
12. Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2011;12(16): 2457-2467.
13. Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries. Eur J Clin Pharmacol. 2013;69 (4):1-10.